Novo Nordisk Swallows the Bitter Pill – Moby THE GIST
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here.
Novo Nordisk raised its full-year outlook after a better-than-expected quarter, but the stock still fell as investors looked past the beat. But oral Wegovy slightly missed expectations, pricing pressure remains heavy, and CagriSema delivered another mixed trial result. Novo is still growing. The market just wants proof it can stop losing the obesity narrative to Eli Lilly.
WHAT HAPPENED
Novo Nordisk reported second-quarter results that were better than feared.
Adjusted sales rose 7% year on year to DKK 78.49 billion ($12.11 billion), while adjusted operating profit increased 11% to DKK 33.39 billion. The company lifted its full-year outlook, saying adjusted sales and operating profit should now fall by 6% to flat at constant exchange rates, better than its previous guidance for a 4% to 12% decline.
Instead of cheering, investors sold the stock down around 5% to 6%.
They focused on the quality of the beat, pricing pressure and whether oral Wegovy can become a big enough growth driver. Sales of the Wegovy pill came in at DKK 3.2 billion, slightly below the DKK 3.3 billion analysts expected. Injectable Wegovy generated DKK 19.48 billion.
Novo also reported disappointing data for CagriSema, its next-generation obesity and diabetes candidate. The drug was broadly in line on weight loss versus Eli Lilly’s tirzepatide, but missed on blood sugar reduction.
CEO Mike Doustdar defended the strategy, saying lower prices are driving volume growth and that oral Wegovy is profitable.
WHY IT MATTERS
Novo Nordisk is learning a brutal market lesson: when you were once priced like a miracle, “pretty good” starts to look like a disappointment.
The company still owns one of the most important pharmaceutical franchises on the planet. Ozempic and Wegovy turned GLP-1 medicines into a cultural, medical and financial phenomenon. Novo helped create the modern obesity drug market, and demand is still enormous.
But investors are no longer asking whether obesity drugs are a blockbuster category. They are asking who controls the next phase: Novo or Eli Lilly.
Lilly’s Zepbound and Mounjaro have gained share fast. Its pipeline looks strong. It’s also pushing into pills, with Foundayo launched in April. Novo, meanwhile, is trying to defend its lead with both injectable and oral Wegovy while repairing faith in its next wave of products. The pill is central to that story.
Story Continues
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
A daily obesity pill could dramatically expand the market. Novo says oral Wegovy has reached more than 5 million prescriptions, and around 80% of patients using it had not previously taken a GLP-1 medicine.
That suggests the pill is not just stealing users from injectable Wegovy. It is bringing new patients into the category.
Doustdar’s argument is basically this: lower prices hurt reported sales, but they unlock volume. If Novo finds the right price-volume balance, the pill can grow the market and still generate profit. That logic is reasonable, but it’s also not enough yet.
The problem is that investors can see the volume, but they can also see the margin risk. A booming obesity market with falling prices is less exciting than one with pricing power. Novo has to show that access, affordability and profitability can coexist. Then there’s the pipeline.
CagriSema was supposed to help Novo answer Lilly’s next-generation challenge. Instead, the latest diabetes trial added more questions. The drug achieved noninferiority on weight loss, with patients losing 15.2% of body weight versus 15.8% for tirzepatide. But it missed on HbA1c reduction, lowering blood sugar by 1.9% versus 2.2%. That’s not a disaster, but it’s not the clean win investors wanted.
The broader pipeline has also had setbacks. Ziltivekimab, a cardiovascular inflammation drug Novo bought through its Corvidia deal, failed to reduce heart attack or stroke risk in a late-stage trial.
That helps explain why Novo is eyeing bolt-on deals. If the internal pipeline is not delivering enough confidence, small acquisitions and licensing deals can fill gaps. But that creates a delicate message: Novo wants to sound disciplined, not desperate.
Novo’s biggest advantage remains scale. It has manufacturing know-how, brand recognition, global reach, massive demand and the strongest legacy in GLP-1s. Oral Wegovy’s early uptake shows there is still a path to growth. But the market has shifted from worship to interrogation.
Novo no longer gets rewarded simply for being in obesity. It has to prove it can win the next version of obesity.
WHAT’S NEXT
Investors will watch oral Wegovy prescriptions, pricing trends, US market share and whether the pill can grow without wrecking profitability. The key tests are CagriSema’s next data readouts, bolt-on deal discipline, competition from Lilly, and whether Novo’s raised guidance turns into durable momentum.
Novo still has the blockbuster. Now it needs a sequel investors actually believe in.